US Stock Market: Whose Results Are Deceptive?
Numbers don't lie, but they don't always tell the whole truth either. In this overview, we examine the Q2 2026 results of the US stock market, where at first glance striking profits or losses hide a completely different reality. Since it has been about a month since the release of the latest reports and investors are slowly starting to prepare for the third quarter earnings season, now is the right time to look beneath the surface and understand what is really going on in these well-known companies.
GILDGilead Sciences (GILD)
Gilead Sciences' second-quarter numbers might be startling at first glance, as the company's operating profit fell by a whopping 520.1% year-over-year, plunging the company into a 10.39 billion dollar loss. However, this massive negative figure is highly misleading, because at the same time, the company's sales revenue growth accelerated to a strong 9.9%, reaching 7.8 billion dollars.
Behind the large accounting loss are actually 11.2 billion dollars in one-off costs resulting from the acquisition of new companies to expand its oncology portfolio. Without this strategic investment, the company's strong sales of HIV and cancer drugs would instead show stable growth. For investors, this means that the short-term paper loss actually hides a strong core business and an expanding product range, which is also confirmed by a recent analyst buy recommendation.
Create a free account to continue
Registration is free - the full analysis with all companies and the conclusion is waiting in the app.
Free account - no credit card needed
The information provided is not investment advice. RYTM analyses are generated with AI assistance and are intended for informational purposes only. Always do your own research before making investment decisions.